Abstract 5991
Background
The E3 ubiquitin ligase Cbl-b is a key master immune checkpoint regulator that limits immune activation critical for anti-tumor immunity. We first reported that Cbl-b deficiency in mice confers spontaneous in vivo rejection of tumor cells. This checkpoint role in anti-tumor immunity was confirmed in multiple mouse and human studies. Further discovery efforts led to the advancement of APN401, an ex vivo human Cbl-b siRNA-based autologous cellular therapy, currently in clinical development in patients with advanced solid tumors. APN401 has been target validated and its preclinical efficacy was established in various mouse syngeneic tumor models. We present here the potent anti-tumor efficacy of APN401 immunotherapy of Cbl-b silenced murine T cells in a syngeneic MC38 colorectal tumor model.
Methods
T cells isolated from MC38 tumor-bearing donor C57Bl/6 mice were silenced ex vivo with APN401 murine Cbl-b specific siRNA vs control siRNA, adoptively transferred into MC38 tumor-bearing recipient mice, and tumor growth was monitored using an in vivo imaging system.
Results
Murine APN401 treatment resulted in a significant MC38 tumor growth inhibition of 63% (p = 0.008) vs controls after just a single dose application. Profound anti-tumor efficacy induced by Cbl-b-silenced T cells strongly correlated with enhanced production of TH1 cytokines IL-2 and IFN-γ. Furthermore, in vivo tracking of fluorescently labeled and silenced T cells revealed migration to relevant lymphoid organs and local tumor sites. Murine APN401 treatment was safe and well-tolerated similar to recent human APN401 clinical phase Ia study results in patients with advanced solid tumors.
Conclusions
In a model of murine colon cancer, Cbl-b-silencing induced vigorous in vivo anti-tumorigenic immune responses. The treatment modality was safe and well tolerated. These data provide direct preclinical proof of concept that siRNA-based silencing of Cbl-b provides a novel, effective and tunable approach as cellular immunotherapy. Targeting Cbl-b through human APN401 cell therapy is a promising novel therapeutic approach for the treatment of solid cancers, also highlighted by our fast-tracked global APN401 clinical development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract